Oncologic Complications and EmergenciesNCT06217783
Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths
A study testing Introcan Safety IV Catheter in people with Oncologic Complications and Emergencies, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
To learn about the effects of the length of the catheter on the failure and success rate of USIV placement. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Oncologic Complications and Emergencies
- What is being tested?
- Introcan Safety IV Catheter
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 400 participants
- Where
- 1 siteUnited States
- Study dates
- 27 Mar 2024to 1 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age > 18 years old.
- Provision of signed and dated informed consent form.
- Predetermined to have difficult IV access necessitating USIV placement
- Expected admission to hospital with anticipated stay > 48 hours (per discussion with treating physician).
Who cannot join
- Expected/anticipated discharge disposition from the ACCC (per discussion with treating physician).
- Inability to give informed consent.
- Pregnant women.
- Non-English speaking participants.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
MD Anderson Cancer Center
Houston, Texas, 77030
Jonathan Rowland, MD, 832-450-8954, jwrowland@mdanderson.org
Jonathan Rowland, MD
About this study
To learn about the effects of the length of the catheter on the failure and success rate of USIV placement.
Read the detailed description
Primary Objectives:
- The rate of catheter failure, defined as removal of the catheter for any reason other than "Care Complete" (i.e. a composite of removal due to "infiltration," "leaking," "catheter damage," "occlusion"), by day 10.
Secondary Objectives:
- Time from catheter placement to removal (i.e. survival or dwell time).
- Per catheter length rate of failure analysis
- Rate of repeat catheterization
- Rate of infection
- Rate of thrombosis
- Conditions
- Oncologic Complications and Emergencies
- Being tested
- Introcan Safety IV Catheter
- Medical subject headings
- Emergencies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Introcan Safety IV CatheterDevice
Given by IV
| Study group | Role | What they receive |
|---|---|---|
| Group A | Experimental | Participants will receive a catheter that is up to 1.75 inches long based on what the nurse thinks is best for you. Receives: Device: Introcan Safety IV Catheter |
| Group B | Experimental | Participants will receive a catheter that is either 1.75 or 2.5 inches long based on what the nurse thinks is best for you. Receives: Device: Introcan Safety IV Catheter |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and adverse events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
Measured: Through study completion; an average of 1 year.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2024
- Study start27 Mar 2024
- Primary completion1 Dec 2027 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oncologic Complications and EmergenciesStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jonathan Rowland, MD, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06217783
- Sponsor's protocol ID
- 2023-0848
- Other IDs
- NCI-2024-00503
- Status last verified
- Jun 2026
- First submitted
- 10 Jan 2024
- Last updated
- 23 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths
- ClinicalTrials.gov ID
- NCT06217783
- Acronym / sponsor ID
- 2023-0848
- Conditions
- Oncologic Complications and Emergencies
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 27 Mar 2024 (actual)
- Primary completion
- 1 Dec 2027 (estimated)
- Study completion
- 1 Dec 2027 (estimated)
- First posted
- 22 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To learn about the effects of the length of the catheter on the failure and success rate of USIV placement.
Detailed description
Primary Objectives:
- The rate of catheter failure, defined as removal of the catheter for any reason other than "Care Complete" (i.e. a composite of removal due to "infiltration," "leaking," "catheter damage," "occlusion"), by day 10.
Secondary Objectives:
- Time from catheter placement to removal (i.e. survival or dwell time).
- Per catheter length rate of failure analysis
- Rate of repeat catheterization
- Rate of infection
- Rate of thrombosis
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A | Experimental | Device: Introcan Safety IV CatheterParticipants will receive a catheter that is up to 1.75 inches long based on what the nurse thinks is best for you. |
| Group B | Experimental | Device: Introcan Safety IV CatheterParticipants will receive a catheter that is either 1.75 or 2.5 inches long based on what the nurse thinks is best for you. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age > 18 years old.
- Provision of signed and dated informed consent form.
- Predetermined to have difficult IV access necessitating USIV placement
- Expected admission to hospital with anticipated stay > 48 hours (per discussion with treating physician).
Key exclusion criteria (4 listed)
- Expected/anticipated discharge disposition from the ACCC (per discussion with treating physician).
- Inability to give informed consent.
- Pregnant women.
- Non-English speaking participants.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Introcan Safety IV CatheterGiven by IV | Device | Group A, Group B |
Primary outcome
Safety and adverse events (AEs)
Time frame: Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2026.
- MD Anderson Cancer CenterLink provided by the sponsor.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jonathan Rowland, MD principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Introcan Safety IV Catheter in people with Oncologic Complications and Emergencies, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jonathan Rowland, MD ((832) 450-8954, jwrowland@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and adverse events (AEs) (time frame: Through study completion; an average of 1 year.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2026.